Tumors in rat kidney generated by initiation with trans-4-acetylaminostilbene and several promoting treatments.
trans-4-Acetylaminostilbene (AAS) is a complete carcinogen in rats and produces quite selectively tumors in Zymbal's glands. On the basis of DNA adduct formation, it has been proposed that this model arylamine initiates neoplastic transformation of cells in many tissues, particularly liver and kidney, which, in the classical sense are considered to be non-target tissues for this chemical. In the present study an initiating treatment with AAS was followed by unilateral nephrectomy and the application of two nephrotoxic substances, gentamycin or beta-cyclodextrin which, among other activities, stimulate cell proliferation specifically in kidney. The initiating dose of AAS, given alone, gave rise to Zymbal's gland and mammary tumors in female Wistar rats within 88 weeks but not to liver or kidney tumors. When the initiation treatment was followed by unilateral nephrectomy, alone or in combination with gentamycin, or by beta-cyclodextrin, four tumors in two out of ten animals, eight tumors in three/ten, and seven tumors in three/ten, respectively, were observed in the kidney. The administered dose of gentamycin was not sufficient to induce tumors on its own. The results support the view that the genotoxic effects of AAS produce promotable lesions in rat kidney. None of the animals that had been treated with AAS, with or without other treatments, developed tumors or the predominant types of preneoplastic lesions in the liver within 88 weeks; this supports the notion that liver, like kidney, is not a target for complete carcinogenesis for this chemical.
Hoffmann
A
A
Institute of Pharmacology and Toxicology, University of Würzburg, Federal Republic of Germany.
Romen
W
W
Neumann
H G
HG
D000238:Adenoma, Chromophobe / Q000139:chemically induced* / Q000473:pathology; D000818:Animals; D002273:Carcinogens; D003043:Cocarcinogenesis; D003505:Cyclodextrins / Q000494:pharmacology*; D003537:Cystadenoma / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D005839:Gentamicins / Q000494:pharmacology*; D007680:Kidney Neoplasms / Q000139:chemically induced* / Q000473:pathology; D009392:Nephrectomy; D051381:Rats; D017208:Rats, Wistar; D013267:Stilbenes / Q000633:toxicity*; D047392:beta-Cyclodextrins
D002273:Carcinogens; D003505:Cyclodextrins; D005839:Gentamicins; D013267:Stilbenes; D047392:beta-Cyclodextrins; C028520:4-acetylaminostilbene; C031215:betadex